Max Healthcare Reports Strong Q2 FY26 Consolidated Results; Board Approves Merger, Divestment, and Dividend
Max Healthcare reported strong consolidated Q2 FY26 results with significant profit growth. The board approved the merger of subsidiaries and divestment of two hospitals, alongside ESOP grants and dividend payment.
The announcement contains key financial results which are critical for investor evaluation. Additionally, multiple significant corporate actions, including a merger, divestment, and ESOP grants, indicate strategic shifts and operational developments that will materially impact the company's future.
The company reported robust financial performance with significant profit growth for both the quarter and half-year. Strategic corporate actions like the NCLT-approved merger and hospital divestment are expected to enhance efficiency and strategic focus, contributing to a positive outlook.
* The Board of Directors of Max Healthcare Institute Limited, in their meeting held on November 14, 2025, approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025. The statutory auditors, S.R. Batliboi & Co. LLP, issued unmodified limited review reports. Consolidated Financial Highlights for Q2 FY26 (Quarter ended September 30, 2025): Revenue from operations stood at ₹2,13,547 lakhs. Total income was ₹2,16,837 lakhs. Profit before tax reached ₹44,603 lakhs. Profit for the period was ₹49,130 lakhs. Basic Earnings Per Share (EPS) was ₹5.05. Consolidated Financial Highlights for H1 FY26 (Half-year ended September 30, 2025): Revenue from operations was ₹4,16,304 lakhs. Total income reached ₹4,23,245 lakhs. Profit before tax amounted to ₹84,646 lakhs. Profit for the period was ₹79,927 lakhs. Basic Earnings Per Share (EPS) was ₹8.22. The merger of Crosslay Remedies Limited (CRL) with Jaypee Healthcare Limited (JHL), both wholly-owned subsidiaries, was approved by the Hon'ble NCLT on November 7, 2025, with an appointed date of October 5, 2024. This resulted in a reversal of current tax and recognition of net deferred tax credit of ₹7,899 lakhs and ₹6,977 lakhs, respectively, during the quarter and half-year ended September 30, 2025. The company granted 2,00,580 stock options to eligible employees under the MHIL ESOP 2022 on August 12, 2025, at an exercise price of ₹900 per share. During the quarter and half-year ended September 30, 2025, the company allotted 89,588 and 94,378 ordinary shares, respectively, under its Employee Stock Option Scheme. Jaypee Healthcare Limited (JHL) divested hospitals located in village Chitta and Anoopshahr (UP) for a total consideration of ₹4,066 lakhs on September 17, 2025, aligning with its strategic focus on super-specialty hospitals in larger cities. A final dividend of ₹1.5 per share for the fiscal year ended March 31, 2025, was approved by shareholders at the Annual General Meeting held on July 30, 2025, and subsequently paid on August 18, 2025.
What to do with a filing like this
Max Healthcare Institute Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Max Healthcare Institute Limited. Read the original for the full detail.